Solna, Sweden, April 25, 2023 – Vivesto AB, an oncology-focused R&D company, today announced that the Annual Report for 2022 has been published. The Annual Report is attached as a PDF and is available on the company’s website,

For further information:
Erik Kinnman, Chief Executive Officer
Phone: +46 18-50 54 40

About Vivesto AB
Vivesto is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of clinical-stage projects targeting advanced cancer. Apealea® (paclitaxel micellar) is made available to patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in long-developed ovarian cancer, and Docetaxel micellar being developed for metastatic prostate cancer. Vivesto’s proprietary and patented technology platform is developed to improve the water solubility, efficacy and safety of pharmaceuticals. The company’s shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit for more information about Vivesto.